Apricus Biosciences, formerly NexMed, announce preclinical data shows NexACT technology enables rectal delivery of biologics, including human antibodies.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including a reshuffle at PhRMA and manoeuvring of directors at OSI Pharmaceuticals and Biogen Idec.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including Genzyme strengthening its quality team and appointments at ISPE and Biogen Idec.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including the retirement of Biogen Idec’s CEO and appointments at Dishman and Noven.
The FDA has approved Biogen Idec to manufacture Tysabri using a high titre process but the product’s sales have been “negatively impacted” by the cases of patients developing PML.
Irish drugmaker Elan, which recently dropped plans to sell its Elan Drug Technologies operation, has announced job cuts and the closure of offices in a bid to save cash.
As more and more delivery firms set their sights on the specialty pharma sector, existing specialty players are increasingly abandoning established licensing strategies in favour of developing drugs in-house to compete.
Pharmaceutical company Enzon may hive off its entire specialty drugs division, including a manufacturing facility in Indianapolis, US, in the face of pressure from shareholder Carl Icahn.
Big pharma's lust for biotech's pipelines appears to be continuing
unabated with a record $27bn-worth of acquisitions and licensing
deals being made last year.
Like countless pets after every Christmas, it seems that nobody
wanted Biogen Idec after all; the firm has announced it will remain
independent after it 'did not receive any definitive offers to
purchase the company'.
Biogen Idec has announced it is seeking a buyer for the company and
has already received several expressions of interest - including a
reputed $23bn (€16.2bn) bid from billionaire corporate raider Carl
Icahn.
Biogen Idec has bagged two new partnerships in the past week which
will see it involved in the search for new drugs for central
nervous system (CNS) and inflammatory ailments.
Investment mogul Carl Icahn could get ready to buy further shares
of biotech company Biogen Idec after getting the green light from
the competition regulators.
